May 27, 2022 – In January 2021, the Department of Health and Human Services (HHS) published a strategic plan to eliminate viral hepatitis by 2030. Hospitals participating in the 340B drug pricing program are a key element of that ambitious goal. They are using their 340B savings to achieve measurable improvements in health outcomes for patients with hepatitis C. National … [Read more...]
340B May Curb High Drug Prices, New JAMA Study Finds
July 9, 2019– The 340B drug pricing program may discourage drug manufacturers from raising prices and instead may have the effect of reducing list prices for certain drugs. That’s according to a new study published in the Journal of the American Medical Association (JAMA). Study authors Sean Dickson of West Health and Ian Reynolds of the Pew Charitable Trusts evaluated the … [Read more...]
340B Helps Achieve Hepatitis C “Gold Standard” At Boston Medical Center
May 17, 2019– A recent study highlights how the 340B drug pricing program helps a safety-net hospital provide critical treatment to patients with Hepatitis C (HCV) and improve health outcomes. Published in the journal PLOS ONE, researchers at Boston Medical Center (BMC) found that the hospital’s 340B savings enabled them to operate a primary-care based multidisciplinary HCV … [Read more...]